Scott T. Tagawa, MD, dives into highlights from ASCO 2024, including notable data on enfortumab vedotin and gemcitabine-cisplatin plus nivolumab.
Professor of Medicine & Urology, Co-Leader, Cancer Therapeutics Program, Meyer Cancer Center, Weill Cornell Medicine, NewYork-Presbyterian Medical Center, New York, NYReceived research grant from: Sanofi; Medivation; Astellas; Janssen; Amgen; Progenics; Dendreon; Lilly; Genentech; Newlink; BMS; Inovio; AstraZeneca
Received income in an amount equal to or greater than $250 from: Sanofi; Medivation; Astellas; Dandreon; Janssen; Genentech; Bayer; Endocyte; Eisai; Immunomedics; Karyopharm; AbbVieimproves response rates, whereas dose reductions and delays are effective for managing toxicity without affecting efficacy. Additional data on this agent from theoutperforms gemcitabine-cisplatin alone, especially in patients with lymph node–only disease.
Malignant Bladder Neoplasm Transitional Cell Carcinoma Urothelial Carcinoma Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Toxicology Toxicity Poisoning Toxins Medical Conferences Professional Societies Fellowship Fellows Adverse Effects Side Effects Lymph Nodes Patient Safety
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
ASCO 2024: Key Insights Into Enhancing Treatment Efficacy and Managing Toxicity in Urothelial CarcinomaThis article summarizes key takeaways from the 2024 American Society of Clinical Oncology (ASCO) conference, focusing on advancements in the treatment of urothelial carcinoma. It highlights new data on enfortumab vedotin (EV) demonstrating improved response rates with higher initial doses while managing toxicity effectively. The article also explores the importance of personalized treatment strategies, including FGFR inhibitors and immune checkpoint inhibitors, and discusses emerging biomarkers and treatment approaches for this disease.
Read more »
Walker Aims to Bounce Back in 2024 After Difficult 2024 SeasonFacing a challenging 2024 season, Phillies pitcher Taijuan Walker is determined to regain his form and secure a prominent role on the team. Walker, who struggled in 2024 with career lows across various pitching metrics, has made significant changes to his offseason routine and is already seeing positive results in his velocity. He remains committed to improving his pitching arsenal, particularly his slider, and is focused on performing at his best regardless of whether he starts or comes out of the bullpen.
Read more »
Unlock Warren Buffett's Stock Picks for 2024 with AI-Powered InsightsGet access to an AI-powered monthly updated list of stock picks that outperformed the S&P 500 in 2024 for less than $9 a month. Learn about Warren Buffett's investment strategies and see which stocks he's adding and removing from his portfolio. Stay ahead of the market with InvestingPro's Best of Buffett strategy.
Read more »
7 insights from 2024's credit card debt trends to help you in 2025Here's the latest for Wednesday, Jan. 29th: Palestinians return to Gaza to find destruction; Residents in Los Angeles return to homes after Palisades fire evacuation orders lifted; Lunar New Year celebrated in Beijing; Sink hole swallows truck in Tokyo.
Read more »
Notre Dame at National Championship: Key Differences Between 2024 and 2012Notre Dame is built a lot differently now than the last time it played in the national championship game.
Read more »
European stocks mixed ahead of key Trump speech; Puma slumps after weak 2024European stocks mixed ahead of key Trump speech; Puma slumps after weak 2024
Read more »